HZNP

Horizon Therapeutics Public Limited Company [HZNP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

HZNP Stock Summary

Earnings have grown 12.48% per last year.

Earnings are expected to fall -100% next year

Profit margins (0.12%) are lower than the previous year (0.14%)

HZNP has less than 1 year of cash runway

In the News

HZNP Financial details

Company Rating

Strong Buy

Market Cap

26.63B

Income

438M

Revenue

3.64B

Book val./share

22.7

Cash/share

10.67

Dividend

Dividend %

Employees

2.19K

Optionable

Shortable

Yes

Earnings

08 Aug 2023

P/E

62.12

Forward P/E

PEG

-32.72

P/S

7.31

P/B

5.12

P/C

10.9

P/FCF

29.39

Quick Ratio

3.5

Current Ratio

4.27

Debt / Equity

0.48

LT Debt / Equity

0.48

EPS (TTM)

1.92

EPS next Y

EPS next Q

EPS this Y

-3.8%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

24.62%

Revenue Q/Q

13.57%

EPS Q/Q

133.33%

SMA20

SMA50

SMA100

Inst Own

60.69%

Inst Trans

0.76%

ROA

ROE

ROC

0.06%

Gross Margin

75%

Oper. Margin

14%

Profit Margin

12%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

60.03-116.38

52W High

+0.26%

52W Low

+93.83%

RSI

Rel Volume

8.4

Avg Volume

2.85M

Volume

23.92M

Perf Week

Perf Month

Perf Quarter

Perf Half Y

Beta

1.01141

Volatility

0%, 0%

Prev Close

Price

116.3

Change

-0.03%

HZNP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	7.27	6.33	10.22	13.69	15.43
Net income per share	-0.45	2.79	1.81	2.27	2.22
Operating cash flow per share	1.17	2.08	2.58	4.39	5.35
Free cash flow per share	1.07	1.99	1.65	3.86	4.81
Cash per share	5.82	5.31	9.75	6.82	10.12
Book value per share	6.34	10.65	18.7	19.83	21.56
Tangible book value per share	-9.01	0.34	8.49	-0.99	2.49
Share holders equity per share	6.34	10.65	18.7	19.83	21.56
Interest debt per share	12.15	7.02	4.94	11.25	11.25
Market cap	3.25B	7.43B	15.75B	25.4B	26.77B
Enterprise value	4.18B	7.71B	14.67B	26.39B	26.98B
P/E ratio	-43.76	12.96	40.41	47.52	51.33
Price to sales ratio	2.69	5.71	7.16	7.87	7.38
POCF ratio	16.69	17.43	28.34	24.53	21.28
PFCF ratio	18.26	18.19	44.26	27.94	23.66
P/B Ratio	3.08	3.4	3.91	5.44	5.28
PTB ratio	3.08	3.4	3.91	5.44	5.28
EV to sales	3.47	5.93	6.67	8.18	7.43
Enterprise value over EBITDA	14.63	20.62	19.11	29.03	24.2
EV to operating cash flow	21.51	18.07	26.41	25.49	21.45
EV to free cash flow	23.54	18.86	41.24	29.03	23.84
Earnings yield	-0.02	0.08	0.02	0.02	0.02
Free cash flow yield	0.05	0.05	0.02	0.04	0.04
Debt to equity	1.8	0.62	0.25	0.55	0.51
Debt to assets	0.46	0.3	0.17	0.3	0.28
Net debt to EBITDA	3.28	0.74	-1.4	1.09	0.19
Current ratio	2.03	2.33	3.51	3.16	3.85
Interest coverage	0.02	1.45	8.22	6.7	7.38
Income quality	-2.62	0.74	1.43	1.94	2.41
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0.42
Research and developement to revenue	0.07	0.08	0.1	0.13	0.12
Intangibles to total assets	0.62	0.48	0.36	0.57	0.49
Capex to operating cash flow	-0.09	-0.04	-0.36	-0.12	-0.1
Capex to revenue	-0.01	-0.01	-0.09	-0.04	-0.03
Capex to depreciation	-0.06	-0.08	-0.72	-0.36	-0.32
Stock based compensation to revenue	0.1	0.07	0.07	0.07	0.05
Graham number	7.98	25.87	27.6	31.81	32.79
ROIC	0	-1.01	0.09	0.09	0.08
Return on tangible assets	-0.05	0.25	0.1	0.14	0.11
Graham Net	-10.54	-4.04	2.71	-7.68	-4.55
Working capital	786.52M	962.93M	2.19B	1.91B	2.7B
Tangible asset value	-1.5B	69.15M	1.83B	-234.43M	586.86M
Net current asset value	-1.54B	-564.48M	1.02B	-1.21B	-389.6M
Invested capital	1.8	0.62	0.25	0.55	0.51
Average receivables	416.04M	436.71M	534.19M	646.24M	654.56M
Average payables	32.48M	25.9M	29.61M	33.92M	92.96M
Average inventory	56.2M	52.28M	64.54M	150.51M	197.64M
Days sales outstanding	140.47	114.74	109.43	71.59	68.03
Days payables outstanding	26.17	21.68	25.84	13.84	61.8
Days of inventory on hand	43.86	54.22	51.58	103.7	67.26
Receivables turnover	2.6	3.18	3.34	5.1	5.37
Payables turnover	13.95	16.83	14.13	26.37	5.91
Inventory turnover	8.32	6.73	7.08	3.52	5.43
ROE	-0.07	0.26	0.1	0.11	0.1
Capex per share	-0.1	-0.09	-0.93	-0.54	-0.54

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.71	3.93	4.04	3.56	4.04
Net income per share	0.26	0.58	0.52	0.23	0.54
Operating cash flow per share	1.06	1.56	1.83	0.37	0.69
Free cash flow per share	1.01	1.43	1.63	0.2	0.61
Cash per share	8.01	9.16	10.22	10.01	10.67
Book value per share	20.94	21.38	21.77	21.8	22.7
Tangible book value per share	1.16	1.93	2.52	2.99	4.29
Share holders equity per share	20.94	21.38	21.77	21.8	22.7
Interest debt per share	10.96	10.99	11.08	11.02	10.98
Market cap	18.84B	14.57B	26.52B	25.52B	24.06B
Enterprise value	19.51B	15B	26.73B	25.76B	24.15B
P/E ratio	77.23	26.81	55.06	116.65	47.34
Price to sales ratio	21.49	15.74	28.15	30.67	25.46
POCF ratio	75.59	39.75	62.19	295.58	149.01
PFCF ratio	78.8	43.27	69.91	540.64	168.25
P/B Ratio	3.81	2.89	5.23	5.01	4.53
PTB ratio	3.81	2.89	5.23	5.01	4.53
EV to sales	22.26	16.21	28.37	30.96	25.56
Enterprise value over EBITDA	81.38	54.28	86.27	198.93	100.09
EV to operating cash flow	78.3	40.94	62.68	298.46	149.59
EV to free cash flow	81.62	44.56	70.47	545.91	168.9
Earnings yield	0	0.01	0	0	0.01
Free cash flow yield	0.01	0.02	0.01	0	0.01
Debt to equity	0.52	0.51	0.51	0.5	0.48
Debt to assets	0.29	0.28	0.28	0.28	0.28
Net debt to EBITDA	2.81	1.57	0.68	1.92	0.38
Current ratio	4.05	3.96	3.85	4.07	4.27
Interest coverage	6.65	7.14	9.37	2.32	11.81
Income quality	4.09	2.7	3.54	1.58	1.27
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0.43	0.4	0	0
Research and developement to revenue	0.12	0.12	0.12	0.16	0.16
Intangibles to total assets	0.53	0.51	0.49	0.49	0.46
Capex to operating cash flow	-0.04	-0.08	-0.11	-0.45	-0.11
Capex to revenue	-0.01	-0.03	-0.05	-0.05	-0.02
Capex to depreciation	-0.1	-0.3	-0.48	-0.41	-0.19
Stock based compensation to revenue	0.05	0.05	0.05	0.07	0.06
Graham number	11.03	16.66	15.91	10.71	16.66
ROIC	0.02	0.02	0.02	0.01	0.02
Return on tangible assets	0.01	0.03	0.03	0.01	0.03
Graham Net	-5.96	-5.35	-4.59	-4.29	-3.71
Working capital	2.41B	2.55B	2.7B	2.72B	3B
Tangible asset value	274.35M	455.46M	586.86M	698.86M	1B
Net current asset value	-704.85M	-582.17M	-389.6M	-295.04M	-65.82M
Invested capital	0.52	0.51	0.51	0.5	0.48
Average receivables	678.91M	659.85M	661.37M	653.2M	673.74M
Average payables	42.78M	25.33M	93.96M	116.21M	81.08M
Average inventory	215.1M	196.97M	179.91M	167.03M	167.41M
Days sales outstanding	69.14	62.87	64.62	68.15	68.33
Days payables outstanding	7.25	12.34	58.23	33.06	35
Days of inventory on hand	79.63	73.13	63.38	70.98	69.69
Receivables turnover	1.3	1.43	1.39	1.32	1.32
Payables turnover	12.42	7.29	1.55	2.72	2.57
Inventory turnover	1.13	1.23	1.42	1.27	1.29
ROE	0.01	0.03	0.02	0.01	0.02
Capex per share	-0.04	-0.13	-0.2	-0.17	-0.08

HZNP Frequently Asked Questions

What is Horizon Therapeutics Public Limited Company stock symbol ?

Horizon Therapeutics Public Limited Company is a IE stock and trading under the symbol HZNP

What is Horizon Therapeutics Public Limited Company stock quote today ?

Horizon Therapeutics Public Limited Company stock price is $116.3 today.

Is Horizon Therapeutics Public Limited Company stock public?

Yes, Horizon Therapeutics Public Limited Company is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 2.85M
Market Capitalization 26.63B
Employee 2.19K
CEO Mr. Timothy P. Walbert
Headquarters Dublin,IE
IPO Date 2011-07-28
Website https://www.horizontherapeutics.com

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.